Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Pembrolizumab in Advanced RCC
NCT04370509Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Feb 2021
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by University of California, San Francisco. Started Feb 2021; status: terminated.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04370509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370509.